Search - tctmd.com

Displaying 41 - 60 of 707

Sort: Relevancy | Date

Congestion Biomarker CA125 Signals Worse Outcomes in Ambulatory HFrEF

News Daily News

Congestion Biomarker CA125 Signals Worse Outcomes in Ambulatory HFrEF

July 03, 2023

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

News Daily News

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

June 05, 2023

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

May 30, 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

May 22, 2023

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

May 12, 2023

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

May 09, 2023

AI Gleans Insights Into Statin Questions, Misinformation Online

News Daily News

AI Gleans Insights Into Statin Questions, Misinformation Online

April 26, 2023

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

April 19, 2023

Myriad Novel Devices Aim to Boost Decongestion in Acute HF

News Features

Myriad Novel Devices Aim to Boost Decongestion in Acute HF

April 10, 2023

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

News Daily News

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

March 27, 2023

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

March 15, 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

March 09, 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

March 08, 2023

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

January 13, 2023

Top Heart Failure News of 2022

News Daily News

Top Heart Failure News of 2022

January 04, 2023

Top Policy and Practice News for Cardiologists in 2022

News Daily News

Top Policy and Practice News for Cardiologists in 2022

January 02, 2023

The Biggest News of 2022: TCTMD’s Top 10

News Opinion Editor's Corner

The Biggest News of 2022: TCTMD’s Top 10

December 30, 2022

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

COVID Vaccine Thrombosis, Thrombocytopenia Risks Clarified in International Study

News Daily News

COVID Vaccine Thrombosis, Thrombocytopenia Risks Clarified in International Study

October 28, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.